Fresolimumab

夫瑞利木单抗

Report date: 2025/05/08 16:35:25

Base Information

Drug NameFresolimumab
Drug Alias Namefresolimumabum夫苏木单抗GC-1008
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTransforming growth factor beta inhibitors
TargetsTransforming growth factor beta
Therapy Area/IndicationsMetastatic breast cancerScleroderma, DiffusePrimary Myelofibrosis +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[8] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCambridge Antibody Technology
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Medical Center GroningenWeill Medical College of Cornell UniversityNational Cancer Institute +[6] 
Active IndicationsN/A
Inactive IndicationsMetastatic breast cancerScleroderma, DiffusePrimary Myelofibrosis +[9] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG